Business
Rhythm Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Update
-- Patient identification and physician engagement ongoing in preparation for U.S. commercial launch in June 2022 in BBS and Alström syndrome, pending FDA
About this update from Rhythm Pharmaceuticals, Inc.
[{"type":"text","content":"-- Patient identification and physician engagement ongoing in preparation for U.S. commercial launch in June 2022 in BBS and Alström syndrome, pending FDA approval -- -- First commercial patients treated with IMCIVREE® (setmelanotide) in France under paid early access program -- -- First patients enrolled in Phase 3 EMANATE trial and Phase 2 DAYBREAK trial -- -- Multiple abstracts accepted for presentation at ENDO 2022 -- -- Management to host conference call today at 8:30 a.m. ET -- BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today reported financial results and provided a business update for the first quarter ended March 31, 2022. “We are excited by the progress we are making towards our long-term vision of transforming the care of individuals living with rare genetic diseases of obesity,” said David Meeker, M.D., Chair, President and Chief Executive Officer of Rhythm. “We continue to build out our U.S. and international commercial organizations while advancing patient identification efforts to support a successful U.S. launch for setmelanotide in Bardet-Biedl and Alström syndromes in June, pending U.S. Food and Drug Administration (FDA) approval. We achieved our first European sales in France during the quarter and continue to have constructive market access discussions with authorities in several key European markets.” Dr. Meeker continued, “Additionally, our robust clinical development program is advancing with patients enrolled in multiple phase 2 and 3 clinical trials. We have optimized our ongoing Phase 3 EMANATE trial to focus exclusively on patient populations with the highest probability of responding to setmelanotide and narrowed our Phase 2 DAYBREAK trial to more efficiently evaluate rare variants associated with ten prioritized genes. In the months ahead, we look forward to reporting interim data from our Phase 2 trial in hypothalamic obesity and our Phase 2 Basket Study in obesity due to a variant in the melanocortin-4 receptor (MC4R).” First Quarter and Recent Business Highlights: Update on Bardet-Biedl and Alström Syndromes: Rhythm continues to execute on ongoing physician and patient education and engagement efforts, as well as patient ...